Medicenna Therapeutics Corp (TSE:MDNA) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Medicenna Therapeutics Corp announced that updated clinical data from its Phase 1/2 ABILITY-1 study will be presented at the 2024 Immunotherapy Bridge Conference. The study evaluates MDNA11, an innovative IL-2 super-agonist, in treating advanced solid tumors. This development underscores Medicenna’s commitment to advancing cancer immunotherapies.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.
